Reactions following completion of 1 and 2 year multidrug therapy (MDT).
We evaluated the incidence, severity, and duration of reactional states in 139 multibacillary (MB) leprosy patients in the first 2 years after the completion of the 1 year regimen of multidrug therapy (MDT) currently recommended by the World Health Organization (WHO) and compared those findings with 295 MB leprosy patients treated with the same regimen previously recommended for 2 years. During the first year after the completion of 1 year MDT, patients experienced 1 or more reactional states 27% of the time, the vast majority being lepra type 1 reactions (reversal reactions, RR), whereas patients who received 2 year MDT experienced a reactional state during that time period only 8% of the time (P < 0.001). Furthermore, during the first year after the completion of therapy, and during the first 2 years, both the number of reactional states and reversal reactions were significantly (P < or = 0.004) more frequent, severe, of longer duration, and more commonly associated with neuritis.
Balagon
Ma Victoria F
MV
Leonard Wood Memorial Center for Leprosy Research, Cebu City, Philippines.
Gelber
Robert H
RH
Abalos
Rodolfo M
RM
Cellona
Roland V
RV
D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D055815:Young Adult
D007917:Leprostatic Agents
World Health Organ Tech Rep Ser. 1982;675:1-33
6806990
Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):195-201
7602214
Lepr Rev. 1996 Dec;67(4):253-9
9033196
Int J Lepr Other Mycobact Dis. 1991 Jun;59(2):255-61
2071983
J Immunol. 1984 Jun;132(6):3085-90
6327818
Int J Lepr Other Mycobact Dis. 1995 Mar;63(1):18-22
7730714
Lepr Rev. 2000 Sep;71(3):318-24
11105490
Lepr Rev. 1994 Dec;65(4):320-32
7861918
J Exp Med. 1989 May 1;169(5):1565-81
2523952
Clin Exp Immunol. 1991 Apr;84(1):103-8
2015700
Clin Exp Immunol. 1995 Feb;99(2):196-202
7851011
Int J Lepr Other Mycobact Dis. 2004 Dec;72(4):493-500
15755209
Int J Lepr Other Mycobact Dis. 1999 Mar;67(1):6-12
10407623
Infect Immun. 2001 May;69(5):3413-7
11292765
Int J Lepr Other Mycobact Dis. 1996 Dec;64(4 Suppl):S21-8
9030120
Lepr Rev. 2000 Jun;71(2):144-53
10920610
Int J Lepr Other Mycobact Dis. 1998 Jun;66(2):159-69
9728448
Clin Exp Immunol. 1976 Apr;24(1):157-67
820499
Lepr Rev. 2000 Sep;71(3):309-17
11105489
World Health Organ Tech Rep Ser. 1998;874:1-43
9627517
Clin Exp Immunol. 1986 Aug;65(2):253-9
2431817
Int J Lepr Other Mycobact Dis. 2004 Jun;72(2):125-33
15301592
Lepr Rev. 1994 Sep;65(3):190-203
8942150
Clin Exp Immunol. 2002 May;128(2):333-8
11985524
Lancet. 1969 Nov 1;2(7627):933-5
4186599
Lepr Rev. 1998 Sep;69(3):225-34
9805878
Int J Lepr Other Mycobact Dis. 2003 Dec;71(4):308-19
14763888
Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):8-15
8326184
Lepr Rev. 1994 Mar;65(1):9-33
8201838